A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

NCT00750334 | Terminated Phase 1

• 1 other identifier: CLOMDS01206
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 3

Brief Summary

This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.

Conditions

Myelodysplastic Syndromes

Keywords

Oral Clofarabine,; relapsed/refractory MDS,; Myelodysplastic

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated dose levels

  First Cycle

Secondary Outcomes (3)

• PK profile

  After MTD is established

• Food effect on profile

  After MTD is established

• Activity of clofarabine in this dosing regimen

  Duration of Study

Study Arms (2)

Part A

EXPERIMENTAL

clofarabine Dose Escalation

Drug: clofarabine

Part B

EXPERIMENTAL

Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.

Drug: clofarabine

Interventions

clofarabine DRUG

Drug given Daily x 14 days and 7 days of rest for 21 day cycle

Part A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide signed, written informed consent.
• Be at least 18 years old.
• Have a pathologically confirmed MDS and score according to the IPSS at study entry. Pathologic confirmation is the responsibility of the investigator.
• Have been treated previously for MDS as follow: a.Patients must have had at least 1, but no more than 2, prior treatment regimens; b.Patients must not have refractory (i.e., disease progression or no evidence of response while on treatment) to more than 1 prior treatment regimen.
• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Be able to comply with study procedures and follow-up examinations.
• Have adequate hepatic and renal function.
• Be non-fertile or agree to use birth control during the study through the end of the last treatment visit and at least 90 days after.

You may not qualify if:

• Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony stimulating factor(G-CSF) or other growth factors within 8 weeks prior to the first dose of oral clofarabine.
• Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks of the first dose of oral clofarabine.
• Have not recovered to ≤ Grade 2 in severity of any drug-related non-hematologic toxicity prior to the first dose of oral clofarabine.
• Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a history of serious disease involving the heart.
• Have a clinically significant cardiac assessment at screening or a known family history QT prolongation.
• Currently uses a medication known to prolong the QT interval.
• Have had any prior treatment with clofarabine (IV or oral).
• Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years after completing curative intent therapy except for the following: a. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment or the condition has been completed. b. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
• Have prior positive test for the human immunodeficiency virus (HIV).
• Have gastrointestinal disease or prior surgery, which may affect the ability of the patient to absorb oral clofarabine.
• Is currently participating in another concurrent investigational protocol that is not restricted to data and/or sample collection for patient demographic and/or disease purposes.

Sponsors & Collaborators

• Genzyme, a Sanofi Company: lead

Study Sites (3)

Malignant Hematology Administration, H. Lee Moffitt Cancer Center

Tampa, Florida, United States

Location

Division of Hematology Mayo Clinic

Rochester, Minnesota, United States

Location

Cancer Care Centers of South Texas

San Antonio, Texas, United States

Location

MeSH Terms

Conditions

Myelodysplastic Syndromes; Recurrence

Interventions

Clofarabine

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Adenine Nucleotides; Purine Nucleotides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Arabinonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Ribonucleotides

Study Officials

• Medical Monitor

  Genzyme, a Sanofi Company

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2008
• First Posted: September 10, 2008
• Study Start: September 1, 2008
• Primary Completion: October 1, 2008
• Study Completion: October 1, 2008
• Last Updated: May 21, 2015

Record last verified: 2015-05

Locations

US (3)